Edition:
United States

Momenta Pharmaceuticals Inc (MNTA.OQ)

MNTA.OQ on NASDAQ Stock Exchange Global Select Market

16.80USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$16.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
185,691
52-wk High
$19.90
52-wk Low
$10.75

Chart for

About

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20... (more)

Overall

Beta: 1.82
Market Cap(Mil.): $1,280.69
Shares Outstanding(Mil.): 76.23
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Momenta Pharmaceuticals posts Q2 loss per share $0.50

* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update

Aug 02 2017

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

Jul 24 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

Jul 21 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

Jul 21 2017

UPDATE 2-U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

Jul 21 2017

U.S. jury sides with Amphastar over Momenta in drug patent trial

BOSTON, July 21 Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

Jul 21 2017

Momenta seeks $938 million from Amphastar at drug patent trial's end

A lawyer for Momenta Pharmaceuticals Inc urged a federal jury on Thursday to force Amphastar Pharmaceuticals Inc to pay $938 million for infringing a patent the drugmaker held through its production of a generic version of the blood-thinner Lovenox.

Jul 20 2017

Momenta, Sandoz face off with Amphastar in blockbuster drug patent trial

Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit took Amphastar Pharmaceuticals Inc to trial Tuesday in a long-running suit over patent infringement that seeks hundreds of millions of dollars in damages over Amphastar's generic version of the blockbuster blood-thinner Lovenox.

Jul 11 2017

BRIEF-Momenta Pharmaceuticals appoints Santiago Arroyo as chief medical officer

* Momenta Pharmaceuticals appoints Santiago Arroyo, M.D., Ph.D. as chief medical officer Source text for Eikon: Further company coverage:

Jun 01 2017

BRIEF-Momenta Pharmaceuticals Q1 loss per share $0.46

* Momenta pharmaceuticals reports first quarter 2017 financial results

May 02 2017

Competitors

Earnings vs. Estimates